 CAMBRIDGE, Mass., Jan. 17, 2023 GLOBE NEWSWIRE -- Omega Therapeutics, Inc. Nasdaq: OMGA Omega, a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it will present a trial-in-progress poster at the upcoming American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium ASCO-GI, taking place in San Francisco, Calif., and virtually, January 1921, 2023. The poster will highlight the design of the ongoing MYCHELANGELOTM I study, a Phase 12 open-label trial evaluating OTX-2002, a first-in-class Omega Epigenomic ControllerTM OEC candidate, for the treatment of hepatocellular carcinoma HCC and other solid tumor types known for association with the c-Myc MYC oncogene. 